SLC5A2 and chronic kidney disease: The reduction in oxidative stress and inflammation through SGLT2 inhibition directly reduces kidney fibrosis; additionally, SGLT2i are associated with improvements in albuminuria, providing further protection against CKD progression in patients with cancer [156].